• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Qiagen N.V. Market Share Analysis - Product Image

Qiagen N.V. Market Share Analysis

  • ID: 1147066
  • December 2011
  • 192 pages
  • GlobalData

FEATURED COMPANIES

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • DiaSorin S.p.A
  • F. Hoffmann-La Roche Ltd.
  • Macherey-Nagel GmbH & Co.
  • Roche Diagnostics Limited
  • MORE

Qiagen N.V. Market Share Analysis

Summary

GlobalData’s new report, “Qiagen N.V. Market Share Analysis” provides in-depth information on Qiagen N.V.’s market position in the different medical equipment markets it operates in. The report provides Qiagen N.V. market share information in two key market categories – Infectious Immunology and Genetic Testing. The report also provides data and information on the overall competitive landscape of the markets, the company operates in. The report is supplemented with global corporate-level profile with information on the company’s business segments, major products and services, competitors, locations and subsidiaries, financial deals and other key developments.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

- Global company shares (in Revenues) information for the key markets Qiagen N.V. operates in – In Vitro Diagnostics.
- Qiagen N.V.’s company shares (in Revenues) information for all the key countries the company has presence READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • DiaSorin S.p.A
  • F. Hoffmann-La Roche Ltd.
  • Macherey-Nagel GmbH & Co.
  • Roche Diagnostics Limited
  • MORE

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
3 Definitions of Markets/Categories Covered
3.1 In Vitro Diagnostics
3.1.1 Genetic Testing
3.1.2 Infectious Immunology
4 Company Snapshot
4.1 Key Information
4.2 Company Overview
4.3 Financial Performance
4.4 SWOT Snapshot
4.5 Business Overview
4.6 Major Products and Services
4.6.1 Overview
5 History
6 SWOT Analysis
6.1 Overview
6.2 Qiagen N.V. Strengths
6.2.1 Broad Product Portfolio
6.2.2 Wide Geographical Presence
6.2.3 Strong Research and Development Activities
6.2.4 Strong Financial Performance
6.3 Qiagen N.V. Weaknesses
6.3.1 Presence of Debt
6.3.2 Pending Litigations
6.4 Qiagen N.V. Opportunities
6.4.1 New Product Launches
6.4.2 Inorganic Growth Strategy
6.4.3 Market Growth in Emerging Economies
6.4.4 Potential Market
6.4.5 Biotech Focus
6.5 Qiagen N.V. Threats
6.5.1 Changing Diagnostic Market Conditions
6.5.2 Stringent Government Regulations
6.5.3 Cost Containment Pressures
6.5.4 Rapid Technological Change
6.5.5 Competitive Landscape
7 Competitors
8 Competitive Landscape
8.1 In Vitro Diagnostics, Global, Market Share (%), 2010
9 Qiagen N.V. Medical Equipment Market Share Analysis
9.1 Qiagen N.V., In Vitro Diagnostics, Global, Market Share (2010)
9.2 Qiagen N.V., Asia-Pacific, Market Share (2010)
9.3 Qiagen N.V., Europe, Market Share (2010)
9.4 Qiagen N.V., Middle East and Africa, Market Share (2010)
9.5 Qiagen N.V., North America, Market Share (2010)
9.6 Qiagen N.V., South and Central America, Market Share (2010)
10 Qiagen N.V. Medical Equipment Market Share Analysis by Category
10.1 Qiagen N.V., In Vitro Diagnostics, Global, Category Revenue Share (2010)
10.2 Qiagen N.V., Asia-Pacific, Category Revenue Share (2010)
10.2.1 Qiagen N.V., Australia, Category Revenue Share (2010)
10.2.2 Qiagen N.V., China, Category Revenue Share (2010)
10.2.3 Qiagen N.V., India, Category Revenue Share (2010)
10.2.4 Qiagen N.V., Japan, Category Revenue Share (2010)
10.2.5 Qiagen N.V., Other Asia-Pacific, Category Revenue Share (2010)
10.3 Qiagen N.V., Europe, Category Revenue Share (2010)
10.3.1 Qiagen N.V., France, Category Revenue Share (2010)
10.3.2 Qiagen N.V., Germany, Category Revenue Share (2010)
10.3.3 Qiagen N.V., Italy, Category Revenue Share (2010)
10.3.4 Qiagen N.V., Spain, Category Revenue Share (2010)
10.3.5 Qiagen N.V., United Kingdom, Category Revenue Share (2010)
10.3.6 Qiagen N.V., Other Europe, Category Revenue Share (2010)
10.4 Qiagen N.V., Middle East and Africa, Category Revenue Share (2010)
10.5 Qiagen N.V., North America, Category Revenue Share (2010)
10.5.1 Qiagen N.V., Canada, Category Revenue Share (2010)
10.5.2 Qiagen N.V., United States, Category Revenue Share (2010)
10.6 Qiagen N.V., South and Central America, Category Revenue Share (2010)
10.6.1 Qiagen N.V., Brazil, Category Revenue Share (2010)
10.6.2 Qiagen N.V., Other South and Central America, Category Revenue Share (2010)
11 Key Employees
12 Key Employee Biographies
13 Locations And Subsidiaries
13.1 Head Office
13.2 Other Locations & Subsidiaries
14 Financial Deals Landscape
14.1 Qiagen N.V., Deals Volume Summary, 2006 to YTD 2011
15 Qiagen N.V. Detailed Deal Summary
15.1 Asset Purchase
15.1.1 QIAGEN Completes Acquisition Of Molecular Diagnostics Distribution Business
15.1.2 QIAGEN Completes Acquisition Of Distribution Business From Diagnostic Technology
15.2 Partnerships
15.2.1 Orion Genomics Enters Into Licensing Agreement With QIAGEN
15.2.2 Mayo Medical Laboratories Enters Into Licensing Agreement With Qiagen
15.2.3 Epigenomics Announces Option Licensing Agreement With QIAGEN
15.2.4 Epigenomics Enters Into Research Licensing Agreement With QIAGEN
15.2.5 Roche Enters Into Licensing Agreement With QIAGEN
15.2.6 QIAGEN Enters Into Licensing Agreement With Johns Hopkins University
15.2.7 QIAGEN Enters Into An Agreement With Roche And Idaho Technology
15.2.8 HandyLab Enters Into An Agreement With Qiagen
15.2.9 Corbett Life Science Enters Into Licensing Agreement With Applied Biosystems Group
15.2.10 QIAGEN Extends Its Agreement With Epigenomics
15.2.11 QIAGEN Enters Into Licensing Agreement With Roche Diagnostics
15.2.12 QIAGEN And Ortho-Clinical Diagnostics Enter Into Licensing Agreement
15.2.13 QIAGEN Enters Into Co-Development Agreement With Eli Lilly
15.2.14 Qiagen Enters Into Co-Development Agreement With Pfizer
15.2.15 Olerup Enters Into Co-Marketing Agreement With QIAGEN
15.2.16 EyeSense Enters Into An Agreement With QIAGEN
15.2.17 QIAGEN Enters Into An Agreement With Abbott
15.2.18 QIAGEN Enters Into An Agreement With Genome Diagnostics
15.2.19 QIAGEN Enters Into Distribution Agreement With Roche Molecular Systems
15.2.20 QIAGEN Enters Into Distribution Agreement With Celera
15.2.21 Center for Molecular Medicine Enters Into Research Agreement With QIAGEN
15.2.22 QIAGEN Forms Joint Venture With Bio One Capital
15.2.23 QIAGEN And Pathway Diagnostics Enter Into Co-Marketing Agreement
15.2.24 SEQUENOM Enters Into An Agreement With QIAGEN
15.2.25 QIAGEN Enters Into Distribution Agreement With Osmetech Molecular Diagnostics
15.2.26 artus Enters Into Distribution Agreement With Corbett Research
15.2.27 Veridex Enters Into Co-Marketing Agreement With QIAGEN
15.2.28 Biosearch Technologies Enters Into An Agreement With QIAGEN
15.2.29 QIAGEN Enters Into Licensing Agreement With BioHelix
15.3 Equity Offering
15.3.1 QIAGEN Completes Private Placement Of Its Common Stock For $640 Million
15.3.2 QIAGEN Completes Private Placement Of Notes Due 2026 For $300 Million
15.4 Acquisition
15.4.1 Qiagen Completes Acquisition Of Cellestis
15.4.2 Qiagen To Acquire 61% Stake In IPSOGEN
15.4.3 QIAGEN Completes Acquisition Of ESE
15.4.4 QIAGEN Completes Acquisition Of SABiosciences
15.4.5 QIAGEN Completes Acquisition Of DxS
15.4.6 QIAGEN Completes Acquisition Of Explera
15.4.7 QIAGEN Acquires Corbett Life Science
15.4.8 QIAGEN Acquires Digene
15.4.9 QIAGEN Acquires eGene
15.4.10 QIAGEN Acquires Genaco Biomedical Products
15.4.11 QIAGEN Acquires Shenzhen PG Biotech
15.4.12 QIAGEN Acquires Tianwei
15.4.13 QIAGEN Acquires QIAGEN Hamburg
15.4.14 QIAGEN Acquires Artus
16 Recent Developments
16.1 Strategy And Business Planning
16.1.1 Nov 28, 2011: QIAGEN Launches Project To Improve Efficiency And Resource Allocation
16.1.2 Aug 08, 2011: QIAGEN Opens Taiwan Subsidiary To Further Expand Presence In Asia
16.1.3 Jan 27, 2011: QIAGEN Establishes Subsidiary In India To Accelerate Expansion
16.1.4 Jun 17, 2010: QIAGEN Expands Partnership With Genome Diagnostics For Development Of New Tests For Applications In Prevention And Personalized Healthcare
16.1.5 Sep 08, 2009: Qiagen Inaugurates New Asia Headquarters In Shanghai
16.1.6 Jun 16, 2009: Qiagen, Linkmed Sign Agreement To Transfer Distribution Rights
16.1.7 Feb 22, 2008: Qiagen Opens New Service Solutions Center In Singapore
16.2 Financial Announcements
16.2.1 Jul 25, 2011: Qiagen Reports Net Sales Of $282.2m In Q2 2011
16.2.2 Apr 27, 2011: Qiagen Reports Net Sales Of $264.3m In Q1 2011
16.2.3 Jan 31, 2011: Qiagen Reports Net Income Of $222.7 Million In 2010
16.2.4 Nov 08, 2010: Qiagen Reports Net Sales Of $274.3m In Q3 2010
16.2.5 Aug 09, 2010: Qiagen Reports Net Income Of $38.52 Million In Q2 2010
16.2.6 May 03, 2010: Qiagen Reports Net Income Of $33 Million In Q1 2010
16.2.7 Feb 08, 2010: Qiagen Reports Net Income Of $137.7 Million In 2009
16.2.8 Nov 09, 2009: Qiagen Reports Net Income Of $37.7 Million In Q3 2009
16.2.9 Aug 10, 2009: Qiagen Reports Net Income Of $30.9 Million In Q2 2009
16.2.10 May 04, 2009: Qiagen Posts Profit Of $24.6 Million In Q1 2009
16.2.11 Feb 09, 2009: Qiagen Reports Preliminary 2008 Results
16.2.12 Nov 10, 2008: Qiagen Reports 3Q 2008 Results
16.2.13 Aug 04, 2008: Qiagen Reports 2Q 2008 Results
16.2.14 May 05, 2008: Qiagen Reports Q1 2008 Results
16.2.15 Feb 11, 2008: Qiagen Reports Q4 2007 Results
16.2.16 Nov 05, 2007: Qiagen Reports Q3 2007 Results
16.2.17 Aug 06, 2007: Qiagen Reports Q2 2007 Results
16.2.18 May 07, 2007: Qiagen Reports Q1 2007 Results
16.2.19 Feb 12, 2007: Qiagen Reports Fiscal Year-End 2006 Results
16.2.20 Nov 13, 2006: Qiagen Reports Q3 2006 Results
16.2.21 Aug 07, 2006: Qiagen Reports Q2 2006 Results
16.3 Research And Development
16.3.1 Jan 12, 2009: QIAGEN led-Consortium Launches Project To Improve In-Vitro Diagnostics
16.3.2 Dec 03, 2007: QIAGEN, Bio-One Establish Dx Assays
16.4 Corporate Communications
16.4.1 Dec 14, 2009: Qiagen Added To NASDAQ-100 Index
16.4.2 Jan 26, 2009: QIAGEN Appoints New President For QIAGEN Japan
16.4.3 Jan 19, 2009: QIAGEN Appoints New Head, Global Regulatory Affairs
16.4.4 May 13, 2008: Qiagen Appoints VP, Molecular Diagnostic Sales For EMEAA
16.5 Legal and Regulatory
16.5.1 Apr 01, 2009: Qiagen Announces CAFC Rejects Third Wave
16.5.2 Jan 22, 2009: QIAGEN And Applied Biosystems Settle All Disputes Over Real-Time PCR Thermal Cycler Patents
16.6 Product News
16.6.1 Aug 05, 2011: QIAGEN Completes Second US Submission For therascreen KRAS RGQ PCR Kit To Guide Treatment Decisions In Colorectal Cancer
16.6.2 Sep 01, 2010: QIAGEN Launches QIAsymphony RGQ System For Molecular Diagnostics
16.6.3 Jul 12, 2010: QIAGEN Announces digene HPV Test Shows Successful Cervical Cancer Control
16.6.4 Jul 06, 2010: Qiagen Receives CE Mark For careHPV Test
16.6.5 Jan 25, 2010: Qiagen Introduces QIAsymphony AS
16.6.6 Jan 18, 2010: Study Finds QIAGEN's Digene HPV Test Effective In Preventing Invasive Cervical Cancer
16.6.7 Sep 10, 2009: QIAGEN Introduces Artus Influenza/H1 RG/LC RT-PCR Kit
16.6.8 Jun 03, 2009: QIAGEN’s Next Generation Molecular Diagnostic Receives CE Mark Approval For KRAS Analysis
16.6.9 May 25, 2009: QIAGEN Announces Launch Of QIAamp Circulating Nucleic Acid Kit For Extraction Of Free Circulating DNA And RNA Fragments
16.6.10 Apr 28, 2009: QIAGEN Provides Screening Tests For Swine Flu Virus
16.6.11 Apr 01, 2009: Landmark Study Shows Significant Reduction In Death Rate From Cervical Cancer With The Digene HPV Test Compared To Other Methods Including Pap
16.6.12 Mar 06, 2009: QIAGEN Supports Cervical Cancer Screening For Underprivileged Chinese Women
16.6.13 Nov 10, 2008: QIAGEN Introduces CE-marked Molecular Assay For The Cancer Biomarker K-ras
16.6.14 Aug 19, 2008: QIAGEN Unveils Diagnostic Assay In The EU To Detect Genetic Variation Causing Adverse Reactions In AIDS Patients
16.6.15 Feb 14, 2008: QIAGEN And Center For Molecular Medicine Create Research Collaboration For Molecular Diagnostic Markers For Breast Cancer, Other Women's Health Issues
16.6.16 May 11, 2007: Digene Research At Clinical Virology Symposium Shows Strides In Multiplex Genotyping Technology Development
16.6.17 Apr 19, 2007: Digene Announces Exclusive Marketing and Distribution Agreement with Asuragen, Inc. for Signature Cystic Fibrosis Screening Products.
17 Appendix
17.1 Research Methodology
17.2 Secondary Research
17.3 Primary Research
17.4 Models
17.5 Forecasts
17.6 Expert Panels
17.7 GlobalData Consulting
17.8 Currency Conversion
17.9 Contact Us
17.10 Disclaimer

1.1 List of Tables
Table 1: Qiagen N.V., Key Facts, 2010
Table 2: Qiagen N.V., SWOT Analysis, 2010
Table 3: In Vitro Diagnostics, Global, Company Share by Revenue ($m), 2010
Table 4: Qiagen N.V., In Vitro Diagnostics, Global, Revenue ($m) and Market Share (%), 2010
Table 5: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Revenue ($m) and Market Share (%), 2010
Table 6: Qiagen N.V., In Vitro Diagnostics, Europe, Revenue ($m) and Market Share (%), 2010
Table 7: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Revenue ($m) and Market Share (%), 2010
Table 8: Qiagen N.V., In Vitro Diagnostics, North America, Revenue ($m) and Market Share (%), 2010
Table 9: Qiagen N.V., In Vitro Diagnostics, South and Central America, Revenue ($m) and Market Share (%), 2010
Table 10: Qiagen N.V., In Vitro Diagnostics, Global, Revenue ($m) and Market Share (%) by Category, 2010
Table 11: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Revenue ($m) and Market Share (%) by Category, 2010
Table 12: Qiagen N.V., In Vitro Diagnostics, Australia, Revenue ($m) and Market Share (%) by Category, 2010
Table 13: Qiagen N.V., In Vitro Diagnostics, China, Revenue ($m) and Market Share (%) by Category, 2010
Table 14: Qiagen N.V., In Vitro Diagnostics, India, Revenue ($m) and Market Share (%) by Category, 2010
Table 15: Qiagen N.V., In Vitro Diagnostics, Japan, Revenue ($m) and Market Share (%) by Category, 2010
Table 16: Qiagen N.V., In Vitro Diagnostics, Other Asia-Pacific, Revenue ($m) and Market Share (%) by Category, 2010
Table 17: Qiagen N.V., In Vitro Diagnostics, Europe, Revenue ($m) and Market Share (%) by Category, 2010
Table 18: Qiagen N.V., In Vitro Diagnostics, France, Revenue ($m) and Market Share (%) by Category, 2010
Table 19: Qiagen N.V., In Vitro Diagnostics, Germany, Revenue ($m) and Market Share (%) by Category, 2010
Table 20: Qiagen N.V., In Vitro Diagnostics, Italy, Revenue ($m) and Market Share (%) by Category, 2010
Table 21: Qiagen N.V., In Vitro Diagnostics, Spain, Revenue ($m) and Market Share (%) by Category, 2010
Table 22: Qiagen N.V., In Vitro Diagnostics, United Kingdom, Revenue ($m) and Market Share (%) by Category, 2010
Table 23: Qiagen N.V., In Vitro Diagnostics, Other Europe, Revenue ($m) and Market Share (%) by Category, 2010
Table 24: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Revenue ($m) and Market Share (%) by Category, 2010
Table 25: Qiagen N.V., In Vitro Diagnostics, North America, Revenue ($m) and Market Share (%) by Category, 2010
Table 26: Qiagen N.V., In Vitro Diagnostics, Canada, Revenue ($m) and Market Share (%) by Category, 2010
Table 27: Qiagen N.V., In Vitro Diagnostics, United States, Revenue ($m) and Market Share (%) by Category, 2010
Table 28: Qiagen N.V., In Vitro Diagnostics, South and Central America, Revenue ($m) and Market Share (%) by Category, 2010
Table 29: Qiagen N.V., In Vitro Diagnostics, Brazil, Revenue ($m) and Market Share (%) by Category, 2010
Table 30: Qiagen N.V., In Vitro Diagnostics, Other South and Central America, Revenue ($m) and Market Share (%) by Category, 2010
Table 31: Qiagen N.V., Key Employees
Table 32: Qiagen N.V., Subsidiaries
Table 33: Qiagen N.V., Deals Volume Summary, 2006 to YTD 2011
Table 34: Qiagen N.V., Deals Summary, 2006 to YTD 2011
Table 35: QIAGEN Completes Acquisition Of Molecular Diagnostics Distribution Business
Table 36: QIAGEN Completes Acquisition Of Distribution Business From Diagnostic Technology
Table 37: Orion Genomics Enters Into Licensing Agreement With QIAGEN
Table 38: Mayo Medical Laboratories Enters Into Licensing Agreement With Qiagen
Table 39: Epigenomics Announces Option Licensing Agreement With QIAGEN
Table 40: Epigenomics Enters Into Research Licensing Agreement With QIAGEN
Table 41: Roche Enters Into Licensing Agreement With QIAGEN
Table 42: QIAGEN Enters Into Licensing Agreement With Johns Hopkins University
Table 43: QIAGEN Enters Into An Agreement With Roche And Idaho Technology
Table 44: HandyLab Enters Into An Agreement With Qiagen
Table 45: Corbett Life Science Enters Into Licensing Agreement With Applied Biosystems Group
Table 46: QIAGEN Extends Its Agreement With Epigenomics
Table 47: QIAGEN Enters Into Licensing Agreement With Roche Diagnostics
Table 48: QIAGEN And Ortho-Clinical Diagnostics Enter Into Licensing Agreement
Table 49: QIAGEN Enters Into Co-Development Agreement With Eli Lilly
Table 50: Qiagen Enters Into Co-Development Agreement With Pfizer
Table 51: Olerup Enters Into Co-Marketing Agreement With QIAGEN
Table 52: EyeSense Enters Into An Agreement With QIAGEN
Table 53: QIAGEN Enters Into An Agreement With Abbott
Table 54: QIAGEN Enters Into An Agreement With Genome Diagnostics
Table 55: QIAGEN Enters Into Distribution Agreement With Roche Molecular Systems
Table 56: QIAGEN Enters Into Distribution Agreement With Celera
Table 57: Center for Molecular Medicine Enters Into Research Agreement With QIAGEN
Table 58: QIAGEN Forms Joint Venture With Bio One Capital
Table 59: QIAGEN And Pathway Diagnostics Enter Into Co-Marketing Agreement
Table 60: SEQUENOM Enters Into An Agreement With QIAGEN
Table 61: QIAGEN Enters Into Distribution Agreement With Osmetech Molecular Diagnostics
Table 62: artus Enters Into Distribution Agreement With Corbett Research
Table 63: Veridex Enters Into Co-Marketing Agreement With QIAGEN
Table 64: Biosearch Technologies Enters Into An Agreement With QIAGEN
Table 65: QIAGEN Enters Into Licensing Agreement With BioHelix
Table 66: QIAGEN Completes Private Placement Of Its Common Stock For $640 Million
Table 67: QIAGEN Completes Private Placement Of Notes Due 2026 For $300 Million
Table 68: Qiagen Completes Acquisition Of Cellestis
Table 69: Qiagen To Acquire 61% Stake In IPSOGEN
Table 70: QIAGEN Completes Acquisition Of ESE
Table 71: QIAGEN Completes Acquisition Of SABiosciences
Table 72: QIAGEN Completes Acquisition Of DxS
Table 73: QIAGEN Completes Acquisition Of Explera
Table 74: QIAGEN Acquires Corbett Life Science
Table 75: QIAGEN Acquires Digene
Table 76: QIAGEN Acquires eGene
Table 77: QIAGEN Acquires Genaco Biomedical Products
Table 78: QIAGEN Acquires Shenzhen PG Biotech
Table 79: QIAGEN Acquires Tianwei
Table 80: QIAGEN Acquires QIAGEN Hamburg
Table 81: QIAGEN Acquires Artus
Table 82: USD to Local Currency, Average Exchange Rate, 2010

1.2 List of Figures
Figure 1: In Vitro Diagnostics, Global, Market Share (%), 2010
Figure 2: Qiagen N.V., In Vitro Diagnostics, Global, Market Share (%), 2010
Figure 3: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Market Share (%), 2010
Figure 4: Qiagen N.V., In Vitro Diagnostics, Europe, Market Share (%), 2010
Figure 5: Qiagen N.V., In Vitro Diagnostics, North America, Market Share (%), 2010
Figure 6: Qiagen N.V., In Vitro Diagnostics, South and Central America, Market Share (%), 2010
Figure 7: Qiagen N.V., In Vitro Diagnostics, Global, Category Revenue Share (%), 2010
Figure 8: Qiagen N.V., In Vitro Diagnostics, Global, Market Share (%) by Category, 2010
Figure 9: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Category Revenue Share (%), 2010
Figure 10: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Market Share (%) by Category, 2010
Figure 11: Qiagen N.V., In Vitro Diagnostics, Australia, Category Revenue Share (%), 2010
Figure 12: Qiagen N.V., In Vitro Diagnostics, Australia, Market Share (%) by Category, 2010
Figure 13: Qiagen N.V., In Vitro Diagnostics, China, Category Revenue Share (%), 2010
Figure 14: Qiagen N.V., In Vitro Diagnostics, China, Market Share (%) by Category, 2010
Figure 15: Qiagen N.V., In Vitro Diagnostics, India, Category Revenue Share (%), 2010
Figure 16: Qiagen N.V., In Vitro Diagnostics, India, Market Share (%) by Category, 2010
Figure 17: Qiagen N.V., In Vitro Diagnostics, Japan, Category Revenue Share (%), 2010
Figure 18: Qiagen N.V., In Vitro Diagnostics, Japan, Market Share (%) by Category, 2010
Figure 19: Qiagen N.V., In Vitro Diagnostics, Other Asia-Pacific, Category Revenue Share (%), 2010
Figure 20: Qiagen N.V., In Vitro Diagnostics, Other Asia-Pacific, Market Share (%) by Category, 2010
Figure 21: Qiagen N.V., In Vitro Diagnostics, Europe, Category Revenue Share (%), 2010
Figure 22: Qiagen N.V., In Vitro Diagnostics, Europe, Market Share (%) by Category, 2010
Figure 23: Qiagen N.V., In Vitro Diagnostics, France, Category Revenue Share (%), 2010
Figure 24: Qiagen N.V., In Vitro Diagnostics, France, Market Share (%) by Category, 2010
Figure 25: Qiagen N.V., In Vitro Diagnostics, Germany, Category Revenue Share (%), 2010
Figure 26: Qiagen N.V., In Vitro Diagnostics, Germany, Market Share (%) by Category, 2010
Figure 27: Qiagen N.V., In Vitro Diagnostics, Italy, Category Revenue Share (%), 2010
Figure 28: Qiagen N.V., In Vitro Diagnostics, Italy, Market Share (%) by Category, 2010
Figure 29: Qiagen N.V., In Vitro Diagnostics, Spain, Category Revenue Share (%), 2010
Figure 30: Qiagen N.V., In Vitro Diagnostics, Spain, Market Share (%) by Category, 2010
Figure 31: Qiagen N.V., In Vitro Diagnostics, United Kingdom, Category Revenue Share (%), 2010
Figure 32: Qiagen N.V., In Vitro Diagnostics, United Kingdom, Market Share (%) by Category, 2010
Figure 33: Qiagen N.V., In Vitro Diagnostics, Other Europe, Category Revenue Share (%), 2010
Figure 34: Qiagen N.V., In Vitro Diagnostics, Other Europe, Market Share (%) by Category, 2010
Figure 35: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Category Revenue Share (%), 2010
Figure 36: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Market Share (%) by Category, 2010
Figure 37: Qiagen N.V., In Vitro Diagnostics, North America, Category Revenue Share (%), 2010
Figure 38: Qiagen N.V., In Vitro Diagnostics, North America, Market Share (%) by Category, 2010
Figure 39: Qiagen N.V., In Vitro Diagnostics, Canada, Category Revenue Share (%), 2010
Figure 40: Qiagen N.V., In Vitro Diagnostics, Canada, Market Share (%) by Category, 2010
Figure 41: Qiagen N.V., In Vitro Diagnostics, United States, Category Revenue Share (%), 2010
Figure 42: Qiagen N.V., In Vitro Diagnostics, United States, Market Share (%) by Category, 2010
Figure 43: Qiagen N.V., In Vitro Diagnostics, South and Central America, Category Revenue Share (%), 2010
Figure 44: Qiagen N.V., In Vitro Diagnostics, South and Central America, Market Share (%) by Category, 2010
Figure 45: Qiagen N.V., In Vitro Diagnostics, Brazil, Category Revenue Share (%), 2010
Figure 46: Qiagen N.V., In Vitro Diagnostics, Brazil, Market Share (%) by Category, 2010
Figure 47: Qiagen N.V., In Vitro Diagnostics, Other South and Central America, Category Revenue Share (%), 2010
Figure 48: Qiagen N.V., In Vitro Diagnostics, Other South and Central America, Market Share (%) by Category, 2010
Figure 49: Qiagen N.V., Deals Volume Summary, 2006 to YTD 2011

Note: Product cover images may vary from those shown

Abbott Laboratories
Alere Inc.
Beckman Coulter, Inc.
Becton, Dickinson and Company
bioMerieux S.A.
Bio-Rad Laboratories, Inc.
DiaSorin S.p.A
EMD Millipore
F. Hoffmann-La Roche Ltd.
Fisher Scientific Corporation
Hologic, Inc.
Life Technologies Corporation
Macherey-Nagel GmbH & Co.
Ortho-Clinical Diagnostics Inc.
Promega Corporation
Roche Diagnostics Limited
Siemens Healthcare
Sigma-Aldrich Corporation
Sysmex Corporation

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos